Anika to defend patent infringement lawsuit for MONOVISC product

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Jul 13 2010Anika Therapeutics, Inc.

Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair, based on hyaluronic acid ("HA") technology, announced today that they had been served with a complaint alleging patent infringement with respect to the MONOVISC product by Genzyme Corporation. This complaint was filed in the United States District Court for the District of Massachusetts on July 7, 2010. The company intends to vigorously defend the lawsuit and the MONOVISC product franchise.

“Management's Discussion and Analysis of Financial Condition and Results of Operations”

Source:

Anika Therapeutics, Inc.

Posted in: Medical Patent News | Pharmaceutical News

Tags: , , , ,

Comments (0)

Suggested Reading

Revvity Signals Software unveils Signals Clinical solution to accelerate critical clinical trial insights and data-driven decisions
Mapping the Microbiome: Dr. Abidemi Junaid on the Groundbreaking Vagina Chip
Study finds patients with long COVID exhibit complement dysregulation with signs of thromboinflammation
New peptide library paves the way for targeting elusive cancer factor MYC
Vaccines targeting chronic diseases show promise in combatting age-related conditions
Promising candidate medication for preventing and reversing fentanyl-induced overdose
AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial
Study reveals inflammation's role in long COVID's lingering effects

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Study suggests high levels of vitamin B3 breakdown products are linked to higher risk of mortality, heart attacks, and stroke